Dr. Agarwal on Potential Agents for Metastatic Hormone-Sensitive Prostate Cancer

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses potential agents for the treatment of patients with metastatic hormone-sensitive prostate cancer.

There are many other agents being tested for the treatment of patients with metastatic hormone-sensitive prostate cancer, explains Agarwal. The SWOG-1216 trial is testing TAK-700, which is similar to abiraterone acetate (Zytiga). This trial has finished accrual and, if results are positive, it can be a potential option for patients.

A novel androgen receptor-blocker, ARN-509, is another agent in an ongoing trial that could be a potential option if it shows promise, states Agarwal.